Abstract: |
60Two major objectives of this investigation are (1) to identify a set of monoclonal antibodies which in combination will bind to all of the myeloma cells and (2) to pursue the identification and characterization of the myeloma progenitor cell,which has been identified as a B lymphocyte. Our ultimate goal is to utilize results of these studies to develop ex vivo methods for purging bone marrow of the tumor cells prior to autologous transplantation. Studies by our laboratory and others have thus far failed to identify any single monoclonal antibody which binds to all of the myeloma cells. However,a few antibodies have been found which label the majority of myeloma cells in most patients,and the use of cocktails of such antibodies for purging appears promising. The identification and elimination of myeloma progenitor cells is complicated by the fact that they are apparently inhomogeneous with respect to phenotype. One group of investigators identified CALLA-positive B lymphoid cells as myeloma progenitors. However,our results suggest that at least some progenitor cells are CALLA-negative. While it appears reasonable to expect that both myeloma cells and their progenitors must be eliminated in order to cure the disease,the relative contribution of these two populations to relapse has not been determined. © 1989 by Taylor & Francis Group,LLC CRC Press is an imprint of Taylor & Francis Group,an Informa business. |